OBJECTIVES: Despite concerns about interchangeability and substitution of biosimilar products with reference products, they provide cost savings either by leading price reductions or increase in discounts of reference products. There are several studies demonstrating the actual/potential cost saving effects of biosimilars. In this regard, the aim of this study is to define the price reductions or increase in discounts of reference products by the reimbursement of their biosimilars in Turkey.  METHODS: Biotechnology products, which are still available in the market, are selected from the list of pharmaceutical products published on the Ministry of Health’s web site. Their registration dates and ex-factory prices and statuary discounts between 2009 and 2014 are searched. Afterwards, the change in the reference products’ ex-factory prices and statuary discounts is analyzed for the first year that biosimilar products are reimbursed. RESULTS: Not considering the different forms of drugs there are 80 biotechnology products (66 active ingredients) being marketed in Turkish pharmaceutical market. 10 of them are biosimilar products (7 active ingredient). The first biotechnology product and the biosimilar product were registered in Turkey in 1992 and 2009 respectively. Only 4 active ingredients have both biosimilar and the reference product. By the reimbursement of the biosimilar products, the average statuary discount of all the reference products is increased by 9.6% and their average public price is decreased by 14.6% CONCLUSIONS: Depending on the analysis, biosimilars may have a cost-reduction impact on pharmaceutical budgets. Further analysis should be conducted on the reason of price reductions of reference products by penetration of biosimilars whether by leading direct reductions or increased discounts in order to exempt the effect or general pricing regulations or cost containment measures unlikely to be specific to biotechnology products.